-+ 0.00%
-+ 0.00%
-+ 0.00%
Ono Pharma partners with Aitia to use causal AI digital twins for neurology drug target discovery
Share
Listen to the news
Ono Pharma partners with Aitia to use causal AI digital twins for neurology drug target discovery
  • ONO Pharmaceutical entered a drug discovery partnership with Aitia focused on neurological diseases using causal AI-based “digital twin” models.
  • Aitia will build Gemini Digital Twins with its REFS technology to identify new therapeutic targets and biomarkers for Ono to pursue.
  • Ono secured exclusive worldwide rights to research, develop, and commercialize drug candidates against targets identified through the collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending